A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel

about

A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel

Item

http://www.wikidata.org/entity/Q41140406

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A preliminary study of 18F-FES ...... or fulvestrant with docetaxel

@en

type

Item

label

A preliminary study of 18F-FES ...... or fulvestrant with docetaxel

@en

prefLabel

A preliminary study of 18F-FES ...... or fulvestrant with docetaxel

@en

P1476

A preliminary study of 18F-FES ...... or fulvestrant with docetaxel

@en

P2093

Biyun Wang

http://www.w3.org/2001/XMLSchema#string

Chengcheng Gong

http://www.w3.org/2001/XMLSchema#string

Chunlei Zheng

http://www.w3.org/2001/XMLSchema#string

Herong Pan

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Jing Xue

http://www.w3.org/2001/XMLSchema#string

Leiping Wang

http://www.w3.org/2001/XMLSchema#string

Yifei Sun

http://www.w3.org/2001/XMLSchema#string

Yingjian Zhang

http://www.w3.org/2001/XMLSchema#string

Yongping Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.

Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.

Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.

P2888

s41598-017-06903-8

P304

6584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-06903-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28747642

http://www.w3.org/2001/XMLSchema#string

P932

5529439

http://www.w3.org/2001/XMLSchema#string